Elan Corp. and Wyeth said a U.S. clinical trial of the drug bapineuzumab suggest the drug can help patients with Alzheimer's disease. In the 18-month Phase 2 trial, bapineuzumab appeared to have clinical activity in treating Alzheimer's, Elan said Tuesday in a news release.

The much anticipated results of a clinical trial of one of the more promising Alzheimer's drugs, released June 17, were mixed at best. But in the Alzheimer's world that qualifies as a success -- and on Wall Street, it was a winner as well. Wyeth Pharmaceuticals (WYE) and Elan Corp.

Federal health officials on Friday said they are hesitant to allow a drug made by Biogen Idec Inc. and Elan Corp. to be used to treat an intestinal disorder because of potentially fatal side effects.

By Jeffrey Krasner, The Boston Globe Dec. 16--Biogen Idec Inc. and Elan Corp. said yesterday that they have applied to the Food and Drug Administration for approval to sell Tysabri, a multiple sclerosis drug, to treat patients with Crohn's disease.

By Penni Crabtree, The San Diego Union-Tribune Jun. 6--Federal regulators yesterday approved the return of Biogen Idec and Elan Corp.'s multiple sclerosis drug Tysabri, but restrictions are likely to put an initial damper on patient use and the companies' profits.